Radiolabeled cyclic RGD peptides as integrin αvβ 3-targeted radiotracers: Maximizing binding affinity via bivalency

Bioconjugate Chemistry

Volumn 20, Issue 12, 2009, Pages 2199-2213

  Liu, Shuang ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BINDING ENERGY; CYTOLOGY; ENDOTHELIAL CELLS; PEPTIDES; RADIOACTIVE TRACERS;

ASPARTIC; BINDING AFFINITIES; ENDOTHELIAL-CELLS; EXTRACELLULAR MATRIX PROTEIN; INTEGRINS; RGD PEPTIDE; TRI-PEPTIDES; TUMOR ANGIOGENESIS; TUMOR UPTAKE; VITRONECTIN;

TUMORS;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 2 MECAPTOACETYLGLYCYLGLYCYL; AH 111585; AH 111585 F18; ARGINYLGLYCYLASPARTIC ACID; CHELATING AGENT; COLLAGEN; COPPER 64; DIAMINEDITHIOL; DIISOPROPYLAMINE DICHLOROACETATE; ECHISTATIN; FIBRINOGEN; FIBRONECTIN; GALACTO ARGINYLGLYCYLASPARTIC ACID F18; GALLIUM 68; IODINE 125; LAMIN; MONOAMINEMONOAMIDEDITHIOL; OSTEOPONTIN; RADIOISOTOPE; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; VITRONECTIN; VITRONECTIN RECEPTOR; VON WILLEBRAND FACTOR;

ADENOVIRUS; AMINO ACID SEQUENCE; BINDING AFFINITY; CANCER INVASION; COST BENEFIT ANALYSIS; DRUG SYNTHESIS; ENDOTHELIUM CELL; HUMAN; ISOTOPE LABELING; METASTASIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; TUMOR GROWTH;

ADENOVIRIDAE;

EID: 72449156995     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc900167c     Document Type: Review

References (134)

1. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31.
2. Mousa, S. A. (1998) Mechanism of angiogenesis in vascular disorders: potential therapeutic targets. Drugs of the Future 23, 51-60.
3. Carmeliet, P. (2000) Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6, 389-395.
4. Meitar, D., Crawford, S. E., Rademaker, A. W., and Cohn, S. L. (1996) Tumor angiogenesis correlates with metastatic disease, N-myc-amplification, and poor outcome in human neuroblastoma. J. Clin. Oncol. 14, 405-414. (Pubitemid 26051001)
5. 3: a new prognostic indicator in breast cancer. Clin. Cancer Res. 4, 2625-2634.
6. Falcioni, R., Cimino, L., Gentileschi, M. P., D'Agnano, I., Zupi, G., Kennel, S. J., and Sacchi, A. (1994) Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human lung carcinoma cells of different histotypes. Exp. Cell Res. 210, 113-122. (Pubitemid 2014093)
7. 3 integrin receptors in breast tumor. J. Exp. Clin. Cancer Res. 20, 585-590.
8. Bögler, O., and Mikkelsen, T. (2003) Angiogenesis in Glioma: molecular mechanisms and roadblocks to translation. Cancer J. 9, 205-213.
9. Folkman, J. (2002) Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15-18.
10. Hwang, R., and Varner, J. V. (2004) The role of integrins in tumor angiogenesis. Hematol. Oncol. Clin. North Am. 18, 991-1006.
11. 3 for angiogenesis. Science 264, 569-571.
12. Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., and Cheresh, D. A. (1995) Definition of two angiogenic pathways by distinct αv integrin. Science 270, 1500-1502. (Pubitemid 3005294)
13. 3 integrin "vitronectin receptor". Int. J. Biochem. Cell Biol. 29, 721-725.
14. Bello, L., Francolini, M., Marthyn, P., Zhang, J. P., Carroll, R. S., Nikas, D. C., Strasser, J. F., Villani, R., Cheresh, D. A., and Black, P. M. (2001) Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 49, 380-389. (Pubitemid 32721066)
15. Albelda, S. M., Mette, S. A., Elder, D. E., Stewart, R. M., Damjanovich, L., Herlyn, M., and Buck, C. A. (1990) Integrin distribution in maliganant melanoma: association of the beta3 subunit with tumor progression. Cancer Res. 50, 6757-6764. (Pubitemid 20348810)
16. Felding-Habermann, B., Mueller, B. M., Romerdahl, C. A., and Cheresh, D. A. (1992) Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J. Clin. Invest. 89, 2018-2022.
17. Zitzmann, S., Ehemann, V., and Schwab, M. (2002) Arginineglycine-aspartic acid (RGD)-peptide binds to both tumor and tumor endothelial cells in vivo. Cancer Res. 62, 5139-5143. (Pubitemid 35024582)
18. Weber, W. A., Haubner, R., Vabuliene, E., Kuhnast, B., Webster, H. J., and Schwaiger, M. (2001) Tumor angiogenesis targeting using imaging agents. Q. J. Nucl. Med. 45, 179-182. (Pubitemid 32640393)
19. Costouros, N. G., Diehn, F. E., and Libutti, S. K. (2002) Molecular imaging of tumor angiogenesis. J. Cell Biol. Suppl. 39, 72-78.
20. van de Wiele, C., Oltenfreiter, R., De Winter, O., Signore, A., Slegers, G., and Dierckx, R. A. (2002) Tumor angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging. Eur. J. Nucl. Med. 29, 699-709. (Pubitemid 34439332)
21. Liu, S., and Edwards, D. S. (2002) Fundamentals of receptor-based diagnostic metalloradiopharmaceuticals. Top. Curr. Chem. 222, 259-278.
22. 3 directed radiopharmaceuticals for tumor imaging. Drugs of the Future 28, 551-564.
23. Haubner, R., and Wester, H. J. (2004) Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of antiangiogenic therapies. Curr. Pharm. Des. 10, 1439-1455. (Pubitemid 38559759)
24. D'Andrea, L. D., Del Gatto, A., Pedone, C., and Benedetti, E. (2006) Peptide-based molecules in angiogenesis. Chem. Biol. Drug Des. 67, 115-126.
25. 3 expression. Mini-Rev. Med. Chem. 6, 227-234.
26. 3-targeted radiotracers for tumor imaging. Mol. Pharm. 3, 472-487.
27. Cai, W., and Chen, X. (2008) Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 49, 113S-128S. (Pubitemid 351948040)
28. Cai, W., Niu, G., and Chen, X. (2008) Imaging of integrins as biomarkers for tumor angiogenesis. Curr. Pharm. Des. 14, 2943-2973. (Pubitemid 351948040)
29. Chen, X. (2008) Advances in anatomic, functional, and molecular imaging of angiogenesis. J. Nucl. Med. 49, 511-514.
30. Jin, H., and Varner, J. (2004) Integrins: roles in cancer development and as treatment targets. Br. J. Cancer 90, 561-565. (Pubitemid 38297190)
31. 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr. Drug Targets 4, 123-131.
32. Meyer, A., Aurenheimer, J., Modlinger, A., and Kessler, H. (2006) Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des. 12, 2723-2747. (Pubitemid 44184633)
33. Van Hagen, P. M., Breeman, W. A. P., Bernard, H. F., Schaar, M., Mooij, C. M., Srinivasan, A., Schmidt, M. A., Krenning, E. P., and de Jong, M. (2000) Evaluation of a radiolabeled cyclic DTPA-RGD analog for tumor imaging and radionuclide therapy. Int. J. Cancer (Radiat. Oncol. Invest.) 90, 186-198. (Pubitemid 30679434)
34. Huabner, R., Wester, H. J., Senekowitsch-Schmidtke, R., Diefenbach, B., Kessler, H., Stöcklin, G., and Schwaiger, M. (1997) RGD-peptides for tumor targeting: biological evaluation of radioiodinated analogs and introduction of a novel glycosylated peptide with improved biokinetics. J. Labelled Compd. Radiopharm. 40, 383-385.
35. Sivolapenko, G. B., Skarlos, D., Pectasides, D., Stathopoulou, E., Milonakis, A., Sirmalis, G., Stuttle, A., Courtenay-Luck, N. S., Konstantinides, K., and Epenetos, A. A. (1998) Imaging of metastatic melanoma utilizing a technetium-99m labeled RGD-containing synthetic peptide. Eur. J. Nucl. Med. 25, 1383-1389. (Pubitemid 28464112)
36. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61, 1781-1785.
37. 3 integrin antagonists: a new class of tracers for tumor imaging. J. Nucl. Med. 40, 1061-1071.
38. Haubner, R., Wester, H. J., Burkhart, F., Senekowisch-Schmidtke, R., Weber, W., Goodman, S. L., Kessler, H., and Schwaiger, M. (2001) Glycolated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42, 326-336. (Pubitemid 32150525)
39. 3 expression. Nuklearmedizin 43, 26-32.
40. Thumshirn, G., Hersel, U., Goodman, S. L., and Kessler, H. (2003) Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chem. - Eur. J. 9, 2717-2725.
41. Poethko, T., Schottelius, M., Thumshirn, G., Herz, M., Haubner, R., Henriksen, G., Kessler, H., Schwaiger, M., and Wester, H. J. (2004) Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochim. Acta 92, 317-327.
42. Poethko, T., Schottelius, M., Thumshirn, G., Hersel, U., Herz, M., Henriksen, G., Kessler, H., Schwaiger, M., and Wester, H. J. (2004) Two-step methodology for high yield routine radiohalogenation of peptides: 18F-labeled RGD and octreotide analogs. J. Nucl. Med. 45, 892-902. (Pubitemid 47618571)
43. 3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-D-Tyr-Lys). Bioconjugate Chem. 18, 530-537.
44. 99mTc-RGD peptides for targeting of integrins in tumor angiogenesis. Anticancer Res. 26, 431-434.
45. 3 integrin for tumor imaging. Bioconjugate Chem. 13, 561-570.
46. 3 expression. Nucl. Med. Biol. 33, 945-952.
47. 64Cu-labeled RGD peptide. Bioconjugate Chem. 15, 41-49.
48. Chen, X., Park, R., Shahinian, A. H., Tohme, M., Khankaldyyan, V., Bozorgzadeh, M. H., Bading, J. R., Moats, R., Laug, W. E., and Conti, P. S. (2004) 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl. Med. Biol. 31, 179-189. (Pubitemid 38315112)
49. 125I-labeled RGD peptide are improved by PEGylation. Nucl. Med. Biol. 31, 11-19.
50. 64Cu-labeled dimeric RGD peptides. Mol. Imaging Biol. 6, 350-359.
51. 18F-labeled dimeric RGD peptide. Mol. Imaging 3, 96-104.
52. 64Cu-labeled tetrameric RGD peptide. J. Nucl. Med. 46, 1707-1718.
53. 18F-FRGD2. J. Nucl. Med. 47, 113-121.
54. 18F-FPRGD4). J. Nucl. Med. 48, 1536-1544.
55. 3 expression. Eur. J. Nucl. Med. Mol. Imaging 35, 1100-1108.
56. 177Lu-labeling of a DOTA-onjugated vitronectin receptor antagonist for tumor therapy. Bioconjugate Chem. 12, 559-568.
57. Janssen, M., Oyen, W. J. G., Massuger, L. F. A. G., Frielink, C., Dijkgraaf, I., Edwards, D. S., Rajopadhye, M., Corsten, F. H. M., and Boerman, O. C. (2002) Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother. Radiopharm. 17, 641-646. (Pubitemid 36025945)
58. 3 integrin binding peptides in a nude mice model. Cancer Res. 62, 6146-6151.
59. Janssen, M. L., Frielink, C., Dijkgraaf, I., Oyen, W. J., Edwards, D. S., Liu, S., Rajopadhye, M., Massuger, L. F., Corstens, F. H. M., and Boerman, O. C. (2004) Improved tumor targeting of radiolabeled RGD-peptides using rapid dose fractionation. Cancer Biother. Radiopharm. 19, 399-404. (Pubitemid 39281331)
60. 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. Bioconjugate Chem. 16, 1580-1588.
61. 3 expression. Bioconjugate Chem. 17, 1069-1076.
62. 99mTc- labeled cyclic RGDfK dimer. Bioconjugate Chem. 17, 1499-1507.
63. 3-positive breast cancer. Bioconjugate Chem. 18, 438-446.
64. Dijkgraaf, I., Liu, S., Kruijtzer, J. A. W., Soede, A. C., Oyen, W. J. G., Liskamp, R. M. J., Corstens, F. H. M., and Boerman, O. C. (2007) Effect of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. Nucl. Med. Biol. 34, 29-35. (Pubitemid 46038156)
65. 3 integrin by multimerization of RGD peptides. Eur. J. Nucl. Med. Mol. Imaging 34, 267-273.
66. 99mTc-labeled cyclic RGDfK tetramer. Nucl. Med. Biol. 35, 111-121.
67. 111In-labeled DTPA conjugates of a cyclic RGDfK dimer. Bioconjugate Chem. 19, 201-210.
68. 99mTc-labeling of HYNIC-conjugated cyclic RGDfK dimer and tetramer using EDDA as coligand. Bioconjugate Chem. 19, 634-642.
69. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem. Rev. 99, 2235-2268.
70. Liu, S. (2004) The role of coordination chemistry in development of target-specific radiopharmaceuticals. Chem. Soc. Rev. 33, 1-18.
71. Liu, S., and Edwards, D. S. (2001) Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjugate Chem. 12, 7-34. (Pubitemid 32113652)
72. Jurisson, S. S., and Lydon, J. D. (1999) Potential technetium small molecule radiopharmaceuticals. Chem. Rev. 99, 2205-2218.
73. 3 integrin expression. J. Nucl. Med. 47, 1172-1180.
74. Welch, M. J., and McCarthy, T. J. (2000) The potential role of generator-produced radiopharmaceuticals in clinical PET. J. Nucl. Med. 41, 315-317. (Pubitemid 30091353)
75. Anderson, C. J., Green, M. A., and Yashi, Y. F. (2003) Chemistry of copper radionuclides and radiopharmaceutical products. In Handbook of Radiopharmaceuticals: Radiochemistry and Applications (Welch, M. J., and Redvanly, C. S., Ed.) pp 401-422, John Wiley & Sons, New York.
76. 62Cu-PTSM. Appl. Radiat. Isot. 43, 1437-1441.
77. 62Cu generator in clinical trials of PET perfusion agent 62Cu- PTSM. J. Nucl. Med. 41, 309-314.
78. Smith, S. V. (2004) Molecular imaging with copper-64. J. Inorg. Biochem. 98, 1874-1901.
79. Blower, P. J., Lewis, J. S., and Zweit, J. (1996) Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl. Med. Biol. 23, 957-980. (Pubitemid 27050682)
80. Reichert, D. E., Lewis, J. S., and Anderson, C. J. (1999) Metal complexes as diagnostic tools. Coord. Chem. Rev. 184, 3-66.
81. 68Ga-labeled peptides in tumor imaging. J. Nucl. Med. 46, 172S-178S.
82. Heppeler, A., Froidevaux, S., Eberle, A. N., and Maecke, H. R. (2000) Receptor targeting for tumor localisation and therapy with radiopeptides. Curr. Med. Chem. 7, 971-994. (Pubitemid 30671305)
83. Heppeler, A., Froidevaux, S., Mäcke, H. R., Jermann, E., Béhé, M., Powell, P., and Hennig, M. (1999) Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour targeting properties and potential for receptor-mediated internal radiotherapy. Chem. - Eur. J. 5, 1974-1981. (Pubitemid 129502685)
84. 3-octreotide: first results in patients with meningiomas. J. Nucl. Med. 42, 1053-1056.
85. Froidevaux, S., Eberle, A. N., Christe, M., Sumanovski, L., Heppeler, A., Schmitt, J. S., Eisenwiener, K., Beglinger, C., and Mäcke, H. R. (2002) Neuroendocrine tumor targeting: study of novel galliumlabeled somatostatin radiopeptides in a rat pancreatic tumor model. Int. J. Cancer 98, 930-937. (Pubitemid 34286693)
86. 68Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med. 28, 1751-1757.
87. 111In-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol. Imaging Biol. 5, 42-48.
88. 68Ga-DOTATOC PET. Eur. J. Nucl. Med. Mol. Imaging 31, 466.
89. 90Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol. Imaging 33, 460-466.
90. 68Ga)-DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) kinetics in patients with meningiomas. J. Nucl. Med. 46, 763-769.
91. 90Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol. Imaging 33, 1115-1122.
92. Liu, S. (2008) Bifunctional coupling agents for target-specific delivery of metallic radionuclides. Adv. Drug Delivery Rev. 60, 1347-1370.
93. 99mTc-labeling of small biomolecules. Top. Curr. Chem. 252, 193-216.
94. André, J., Maecke, H., Zehnder, M., Macko, L., and Akyel, K. (1998) 1,4,7-triazanonane-1-succinic acid-4,7-diacetic acid (NODASA): a new bifunctional chelator for radio gallium-labeling of biomolecules. Chem. Commun. 12, 1301-1302. (Pubitemid 128675619)
95. 2) expressing tumors. Bioconjugate Chem. 13, 530-541.
96. Eisenwiener, K. P., Powell, P., and Maecke, H. R. (2000) A convenient synthesis of novel bifunctional pro-chelators for coupling to bioactive peptides for radiometal labeling. Bioorg. Med. Chem. Lett. 10, 2133-2135. (Pubitemid 30688407)
97. 11), a cyclized peptide analogue of α-MSH. J. Med. Chem. 48, 2985-2992.
98. 2] targeting vector for positron-emission tomography imaging of gastrin- releasing peptide receptor-expressing tissues. Proc. Natl. Acad. Sci. U.S.A. 104, 12462-12467.
99. 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother. Radiopharm. 18, 627-641.
100. 3 receptor antagonist: different but biologically equivalent. Bioconjugate Chem. 15, 235-241.
101. Harris, T. D., Cheesman, E., Harris, A. R., Sachleben, R., Edwards, D. S., Liu, S., Bartis, J., Ellars, C., Onthank, D., Yalamanchili, P., Heminway, S., Silva, P., Robinson, S., Lazewatsky, J., Rajopadhye, M., and Barrett, J. A. (2007) Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging Agents. Bioconjugate Chem. 18, 1266-1279. (Pubitemid 47122650)
102. 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents. Bioconjugate Chem. 17, 1294-1313.
103. 3-targeted imaging of lung cancer. Neoplasia 7, 271-279.
104. 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J. Nucl. Med. 50, 116-122.
105. 18F-AH111585 in breast cancer patients. J. Nucl. Med. 49, 879-886.
106. 3-selective tracer 18F-Galacto-RGD in cancer patients. J. Nucl. Med. 46, 1333-1341.
107. 18F]Galacto-RGD. PLOS Medicine 2 e70, 244-252.
108. 3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13, 6610-6616.
109. 18F-Galacto-RGD PET. J. Nucl. Med. 49, 255-259.
110. 3 integrin for a new cancer therapy. Angew. Chem., Int. Ed. Engl. 36, 1375-1389.
111. 3 antagonists. J. Am. Chem. Soc. 118, 7461-7472.
112. Aumailley, M., Gurrath, M., Müller, G., Calvete, J., Timpl, R., and Kessler, H. (1991) Arg-Gly-Asp constrained within cyclic pentapeptides strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 291, 50-54.
113. Gottschalk, K. E., and Kessler, H. (2002) The structures of integrins and integrin-ligand complexes: Implications for drug design and signal transduction. Angew. Chem., Int. Ed. Engl. 41, 3767-3774.
114. 5 antagonist, rapidly detects spontaneous tumors in mice and dogs. 47th Annual Meeting of SNM, St. Louis, Missouri. J. Nucl. Med. 41, 34P.
115. Liu, S., Edwards, D. S., Ziegler, M. C., Harris, A. R., Hemingway, S. J., and Barrett, J. A. (2001) 99mTc-Labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumor. Bioconjugate Chem. 12, 624-629. (Pubitemid 32696237)
116. Boturyn, D., Coll, J. L., Garanger, E., Favrot, M. C., and Dumy, P. (2004) Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J. Am. Chem. Soc. 126, 5730-5739. (Pubitemid 38621412)
117. 3 integrin expression. J. Nucl. Med. 48, 1162-1171.
118. 4 linkers. Mol. Pharm. 6, 231-245.
119. 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J. Med. Chem. 51, 7980-7990.
120. Cai, W., Rao, J., Gambhir, S. S., and Chen, X. (2006) How molecular imaging is speeding up antiangiogenic drug development? Mol. Cancer Ther. 5, 2624-2633. (Pubitemid 44848989)
121. Niu, G., and Chen, X. (2008) Has molecular and cellular imaging enhanced drug discovery and drug development? Drugs in R&D 9, 351-368.
122. Jain, R. K. (1987) Transport of molecules in the tumor interstitium: a review. Cancer Res. 47, 3039-3051.
123. 4 Linkers. Bioconjugate Chem. 20, 750-759.
124. 4 Linkers. Dalton Trans. .
125. 3 PET imaging. Eur. J. Nucl. Med. Mol. Imaging 36, 947-957.
126. 4 linkers. Eur. J. Nucl. Med. Mol. Imaging ASAP.
127. Fani, M., Andre, J. P., and Maecke, H. R. (2008) 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contr. Media Mol. Imaging 3, 53-63. (Pubitemid 351722193)
128. 18F-radiopharmacy. Ernst Schering Res. Found. Workshop 62, 215-242.
129. Al-Nahhas, A., Win, Z., Szyszko, T., Singh, A., Khan, S., and Rubello, D. (2007) What can gallium-68 PET add to receptor and molecular imaging. Eur. J. Nucl. Med. Mol. Imaging 34, 1897-1901. (Pubitemid 350212142)
130. Creamer, D., Allen, M., Sousa, A., Poston, R., and Barker, J. (1995) Altered vascular endothelium integrin expression in psoriasis. Am. J. Pathol. 147, 1661-1667.
131. 3 integrin-targeted fluorochrome. J. Nucl. Med. 49, 1845-1851.
132. Meoli, D. F., Sadeghi, M. M., Krassilnikova, S., Bourke, B. N., Giordano, F. J., Dione, D. P., Su, H. L., Edwards, D. S., Liu, S., Harris, T. D., Madri, J. A., Zaret, B. L., and Sinusas, A. J. (2004) Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J. Clin. Invest. 113, 1684-1691. (Pubitemid 39071660)
133. 18F-Galacto-RGD. J. Nucl. Med. 46, 184-189.
134. 3 integrin after murine hindlimb ischemia. Circulation 111, 3255-3260.